Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY3076226
- Development stage
- Phase 1
- Lead developer
- Eli Lilly
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
LY3076226 is an investigational antibody-drug conjugate (ADC) developed by Eli Lilly. It consists of a human IgG1 monoclonal antibody targeting fibroblast growth factor receptor 3 (FGFR3), conjugated via a cleavable linker to the cytotoxic agent DM4, a maytansine derivative that inhibits tubulin dynamics. The ADC selectively binds to both wild-type and mutant forms of FGFR3, including TACC3 fusion proteins, leading to internalization and targeted delivery of the cytotoxin into cancer cells with aberrant FGFR3 activation. This results in inhibition of cell division and induction of apoptosis in tumor cells. LY3076226 has been evaluated in phase I clinical trials for advanced or metastatic cancers, including urothelial carcinoma with FGFR3 alterations[1][2][4][5][6].
- Other names
- anti-FGFR3 antibody-drug conjugateanti-FGFR-3 antibody-drug conjugateanti-FGFR 3 antibody-drug conjugateanti-fibroblast growth factor receptor 3 antibody-drug conjugate
02
Targets
FGFR3 (Fibroblast growth factor receptor 3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on LY3076226.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY3076226.